A new once-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages along with ESR1 mutations, according to phase-3 trials conducted by the ...

In the all-patient population, which included 354 patients without ESR1 mutations, median PFS was not significantly improved with vepdegestrant (median 3.8 vs 3.6 months with fulvestrant; HR 0.83 ...

Quick Take Vepdegestrant in ESR1 -Mutant Breast Cancer August 6, 2025 DOI: 10.1056/NEJMdo008080 Save ...

It's worth noting that neither of Roche's phase 3 trials – PERSEVERA in the first-line setting and LIDERA as adjuvant treatment – appear to have ESR1 enrichment built into the design.

For the overall group, there was a 30% improvement in PFS, at 22% at 12 months for Orserdu versus 9% for the control therapies, and almost 27% and 8%, respectively, for the ESR1 subgroup.

"Patients often face limited treatment options after first-line treatment and vepdegestrant demonstrated improved progression-free survival in patients with ESR1-mutated ER+/HER2- advanced breast ...

(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with ...

The poster, " Vaginal/vulvar symptoms with lasofoxifene versus fulvestrant in ESR1-mutated, ER+/HER2- metastatic breast cancer patients," will be presented Saturday, March 4, at the Marriott St ...

For patients with ESR1 mutations who were treated with CDK4/6i for ≥12 months prior to randomization on EMERALD, elacestrant achieved a median PFS of 8.6 months versus 1.9 months on SOC, with a ...